CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research

Executive Summary: CP-673451 is a highly selective ATP-competitive inhibitor of PDGFRα and PDGFRβ with IC50 values of 10 nM and 1 nM, respectively, showing over 180-fold selectivity against c-Kit in cellular assays (ApexBio). In vivo, oral administration at 50 mg/kg in rat C6 glioblastoma xenografts reduces PDGFR-β phosphorylation by >50% for four hours and inhibits angiogenesis by 70-90% in a mouse model (Pladevall-Morera et al., 2022). CP-673451 demonstrates robust suppression of tumor growth and microvessel density in multiple xenograft models. Its high selectivity over VEGFR, EGFR, and other kinases ensures precise pathway interrogation. This article details evidence, mechanisms, applications, and parameters for effective use in cancer research workflows.

Biological Rationale

Platelet-derived growth factor receptors (PDGFRα and PDGFRβ) are receptor tyrosine kinases (RTKs) central to cell proliferation, differentiation, and angiogenesis. Aberrant PDGFR signaling is implicated in tumorigenesis, particularly in glioblastomas and other solid tumors (Pladevall-Morera et al., 2022). ATRX mutations, common in high-grade gliomas, are associated with increased PDGFR pathway activation and sensitivity to PDGFR inhibition. Selective PDGFR inhibitors allow researchers to probe these signaling pathways and develop targeted anti-angiogenic therapies. CP-673451's high selectivity profile makes it a valuable tool for distinguishing PDGFR-driven effects from off-target kinase activities.

Mechanism of Action of CP-673451

CP-673451 (1-[2-[5-(2-methoxyethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine, MW 417.52, C₂₄H₂₇N₅O₂) functions as an ATP-competitive inhibitor, binding to the kinase domains of PDGFRα and PDGFRβ and preventing phosphorylation events essential for downstream signaling (ApexBio). This inhibition blocks PDGF-driven angiogenesis and cell proliferation. In cellular assays, CP-673451 inhibits PDGFRβ with an IC50 of 6.4 nM (PAE-β cells), and demonstrates >180-fold selectivity over c-Kit in H526 cells. The compound is highly selective over VEGFR-1, VEGFR-2, Lck, TIE-2, and EGFR, with only moderate inhibition of c-Kit (IC50 = 1.1 μM). High selectivity ensures minimal off-target effects, supporting clean mechanistic studies.

Evidence & Benchmarks

• CP-673451 inhibits PDGFRα and PDGFRβ kinase activity with IC50 values of 10 nM and 1 nM, respectively (ApexBio).
• In PAE-β cells, CP-673451 shows an IC50 of 6.4 nM for PDGFRβ inhibition and >180-fold selectivity over c-Kit in H526 cells (ApexBio).
• Oral administration at 50 mg/kg in rat C6 glioblastoma xenograft models reduces PDGFR-β phosphorylation by >50% for four hours (ApexBio).
• In mouse sponge angiogenesis models, CP-673451 inhibits PDGF-BB-induced angiogenesis by 70-90% (ApexBio).
• Multiple xenograft models (Colo205, LS174T, H460, U87MG) exhibit suppressed tumor growth and reduced microvessel density after CP-673451 administration (Pladevall-Morera et al., 2022).
• ATRX-deficient high-grade glioma cells display increased sensitivity to RTK and PDGFR inhibitors, including CP-673451 (Pladevall-Morera et al., 2022).

For a detailed discussion on strategic application in translational workflows, see Redefining Precision in PDGFR Signaling, which this article updates with recent evidence in ATRX-deficient models.

Applications, Limits & Misconceptions

CP-673451 is used to dissect PDGFR signaling, evaluate angiogenesis inhibition, and measure tumor growth suppression in preclinical cancer models. It is especially valuable in ATRX-deficient glioblastoma research, where PDGFR pathway dependency is pronounced (Pladevall-Morera et al., 2022). The compound is also employed in angiogenesis inhibition assays and to benchmark new PDGFR-targeting agents.

For broader context, Precision PDGFR Tyrosine Kinase Inhibition Beyond the Bench explores translational implications, while this article provides updated benchmarks for ATRX-deficient glioma sensitivity.

Common Pitfalls or Misconceptions

• CP-673451 is not effective against non-PDGFR-driven tumors; efficacy is reduced where PDGFRα/β are not key drivers (Pladevall-Morera et al., 2022).
• Moderate inhibition of c-Kit (IC50 = 1.1 μM) may confound results in models where c-Kit is highly expressed.
• The compound is insoluble in water; improper solubilization may impact reproducibility. Recommended solvents are DMSO (≥20.9 mg/mL) and ethanol (≥2.39 mg/mL, with warming and ultrasonic treatment).
• Long-term storage of solutions reduces activity; use freshly prepared solutions or store DMSO stocks below -20°C for several months only (ApexBio).
• Results from animal xenograft models may not fully extrapolate to human clinical outcomes due to species-specific differences.

Workflow Integration & Parameters

CP-673451 is supplied as a powder, SKU B2173 (product page). For in vitro work, dissolve in DMSO or ethanol under warming and ultrasonic conditions. For in vivo studies, oral gavage at 50 mg/kg is established in rat C6 glioblastoma xenograft protocols. Storage at -20°C is required; short-term use of solutions is recommended. CP-673451 facilitates robust interrogation of PDGFR signaling and angiogenesis in both cellular and animal models. In workflows studying ATRX-deficient gliomas, combinatorial regimens with temozolomide may be explored for enhanced efficacy (Pladevall-Morera et al., 2022).

For troubleshooting and advanced applications, CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research offers complementary protocol optimization guides, whereas this article focuses on selectivity and ATRX context.

Conclusion & Outlook

CP-673451 is a validated, selective PDGFRα/β inhibitor for cancer research, with proven nanomolar efficacy and robust in vivo anti-angiogenic activity. Its utility is exemplified in ATRX-deficient glioma models, where PDGFR pathway targeting yields pronounced effects. Ongoing research will refine its translational applications, especially in combinatorial regimens and precision oncology workflows. The B2173 kit remains a cornerstone for mechanistic studies and preclinical validation of PDGFR-centric therapies.